# PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)

> **NCT00724620** · PHASE4 · COMPLETED · sponsor: **Schering-Plough** · enrollment: 103 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** Peginterferon alfa-2b (SCH 054031)
- **DRUG:** Ribavirin (SCH 018908)

## Key facts

- **NCT ID:** NCT00724620
- **Lead sponsor:** Schering-Plough
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2008-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724620, "PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00724620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*